Product description : Crizotinib is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive. Crizotinib is the first FDA
Product Features:
| Product Name | :Crizonix |
| Generic Name | : Crizotinib |
| Formulation | : Capsule |
| Available Pack Size | : 28’s |
| Available Strengths | : 250mg |
| Registrations | : Oncology |
